Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2022 | The pathogenesis and treatment of Evans syndrome

V. Koneti Rao • 13 Jun 2022

EHA 2022

Activated PI3K Delta Syndrome Anemias Evans Syndrome Immune Thrombocytopenia Non-Malignant

V. Koneti Rao, MD, FRCPA, National Institute of Allergy and Infectious Diseases, Bethesda, MD talks on the pathogenesis and treatment of Evans syndrome (ES), defined as an autoimmune condition that presents with two or more cytopenias – commonly autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Dr Rao emphasizes the importance of conducting a genetic evaluation of patients diagnosed with Evans syndrome to allow for specific, targeted treatment. Dr Rao also explains that in the future, striving toward more genetically or epigenetically targeted treatments is key in the management of chronic disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Insights into the pathogenesis and treatment of autoimmune lymphoproliferative syndrome

V. Koneti Rao • 13 Jun 2022

The importance of family history in the diagnosis and management of hematological malignancies

V. Koneti Rao • 13 Jun 2022

The management of patients with activated PI3K delta syndrome

V. Koneti Rao • 13 Jun 2022

Phase III study of leniolisib in patients with activated PI3K delta syndrome

V. Koneti Rao • 13 Jun 2022

Related Videos

The MDT in the new era of gene therapy for hemoglobinopathies

Mattia Algeri • 15 Apr 2024

Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases

Rita Beier • 15 Apr 2024

Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH

Carlo Dufour • 15 Apr 2024

A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia

Antonio Risitano • 16 Apr 2024